Business Insight & People News
Laboratory Analytical Instruments
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. How we calculate this.
Revenue and net income below are for fiscal period FY2024, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
| Officers 1 | ||||
| David Patience | CFO | 65,328 | Not available | M Option exercise or conversion Apr 1, 2025 position reported |
| Directors 3 | ||||
| Jack W. Schuler | Board Member | 8,336,110 | Not available | S Open-market sale Dec 3, 2024 position reported |
| John Patience | Board Member | 871,211 | Not available | P Open-market purchase Dec 3, 2024 position reported |
| Hany Massarany | Board Member | 39,891 | Not available | M Option exercise or conversion Jun 28, 2024 position reported |
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | David Patience | M Option exercise or conversion | 20,000 | $0.00 | $0 | SEC filing ↗ |
| Apr 1, 2025 | David Patience | S Open-market sale | 6,816 | $0.71 | $4.8K | SEC filing ↗ |
| Feb 26, 2025 | David Patience | M Option exercise or conversion | 1,500 | $0.00 | $0 | SEC filing ↗ |
| Feb 26, 2025 | David Patience | S Open-market sale | 535 | $1.09 | $583 | SEC filing ↗ |
| Dec 3, 2024 | John Patience | P Open-market purchase | 200,000 | $1.57 | $314.0K | SEC filing ↗ |
| Dec 3, 2024 | Jack W. Schuler | S Open-market sale | 200,000 | $1.57 | $314.0K | SEC filing ↗ |
| Jun 28, 2024 | Hany Massarany | M Option exercise or conversion | 4,737 | $0.00 | $0 | SEC filing ↗ |
| Jun 28, 2024 | Jack W. Schuler | M Option exercise or conversion | 4,737 | $0.00 | $0 | SEC filing ↗ |
| May 29, 2024 | Hany Massarany | M Option exercise or conversion | 7,894 | $0.00 | $0 | SEC filing ↗ |
| May 29, 2024 | Jack W. Schuler | M Option exercise or conversion | 7,894 | $0.00 | $0 | SEC filing ↗ |
| May 20, 2024 | Jack W. Schuler | A Grant or award | 1,560,694 | $0.00 | $0 | SEC filing ↗ |
| Apr 9, 2024 | David Patience | S Open-market sale | 13,296 | $0.87 | $11.6K | SEC filing ↗ |
| Apr 9, 2024 | David Patience | M Option exercise or conversion | 37,468 | $0.00 | $0 | SEC filing ↗ |
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
The report an officer, director or large shareholder must file after trading their own company’s stock.
8 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.
This is not the full list. SEC rules only require a company to name its significant subsidiaries.
Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.
| Subsidiary | Organised in |
|---|---|
| Accelerate Diagnostics B.V. | Netherlands |
| Accelerate Diagnostics GmbH | Germany |
| Accelerate Diagnostics Holdings, LLC | United States |
| Accelerate Diagnostics Pty Ltd | Australia |
| Accelerate Diagnostics S.L. | Spain |
| Accelerate Diagnostics S.r.l | Italy |
| Accelerate Diagnostics SARL | France |
| Accelerate Diagnostics UK Limited | England |
A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.